Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Vertex Pharmaceuticals — PDUFA Date: Casgevy | Humanexa Signals | Humanexa Signals

Catalyst

Vertex Pharmaceuticals — PDUFA Date: Casgevy

Vertex Pharmaceuticals — PDUFA Date — Casgevy in Sickle cell disease.

Strategic implication

First CRISPR-based therapy PDUFA sets precedent for gene-editing commercialization timelines.

Date

June 20, 2026

Phase

NDA/BLA

Status

confirmed

Signal score

9.4

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.